You are now leaving the Lilly Medical website
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Foundayo ™ (orforglipron) tablet
0.8 mg / 2.5 mg / 5.5 mg / 9 mg / 14.5 mg / 17.2 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
What lifestyle modifications, including diet and exercise, were recommended in the Foundayo™ (orforglipron) weight management studies?
In ATTAIN-1 and ATTAIN-2, participants received lifestyle management counseling, including recommendations on diet and physical activity, with the goal of achieving weight reduction.
See important safety information, including boxed warning, in the attached prescribing information.
Lifestyle Recommendations
In the orforglipron weight management studies, ATTAIN-1 and ATTAIN-2, participants received lifestyle management counseling, including recommendations on diet and physical activity with the goal of achieving weight reduction. No specific range of calorie deficit was specified in the ATTAIN-1 and ATTAIN-2 study protocols.1,2
Meals and Dietary Restrictions
During the studies, individualized counseling on a healthy diet was provided by a dietitian, nutritionist, or equivalent qualified designee. The goal was to promote healthier food choices and portion control through mindful eating. Counseling included guidance on nutrient-dense food and beverage choices tailored to personal preferences, cultural traditions, and budgetary considerations. Key principles included
-
eating smaller, more frequent meals/snacks every 3 to 4 hours
-
avoiding skipped meals
-
structuring meals with approximately ½ plate of fruits/vegetables, ¼ plate of whole grains, and ¼ plate of protein
-
including fiber-rich foods, and
-
limiting foods high in solid fats, added sugar, and salt.1,2
During the studies, medical staff were advised to consider monitoring participants’ nutritional and hydration status, particularly for those with significantly reduced caloric intake (eg, below 800-1200 kcal), to identify early signs of poor intake or dehydration and take preventive actions to reduce the risk of complications.1,3
Physical Activity
Participants were advised to achieve a healthy physical activity level of at least 150 minutes per week, as tolerated. Adherence to physical activity goals was assessed at each study visit. To encourage adherence, participants were recommended to complete a 3-day diet and physical activity log prior to each counseling visit.1-3
Enclosed Prescribing Information
FOUNDAYO™ (orforglipron) tablets, for oral use, Lilly
References
The published references below are available by contacting 1-800-LillyRx (1-800-545-5979).
- Wharton S, Aronne LJ, Stefanski A, et al; ATTAIN-1 Trial Investigators. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. N Engl J Med. 2025;393(18):1796-1806. https://doi.org/10.1056/NEJMoa2511774
- Horn DB, Ryan DH, Giljanovic Kis S, et al; ATTAIN-2 Trial Investigators. Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial. Lancet. 2025;406(10522):2927-2944. https://doi.org/10.1016/S0140-6736(25)02165-8.
- Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Date of Last Review: April 01, 2026